Utilization of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention
European Journal of Clinical Pharmacology · 2023-04 · 79 (4) · 541-551
DOI: 10.1007/s00228-023-03468-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Clinical Pharmacology, online erschienen am 24.02.2023. Verfasst von Hye-Jeong Choi und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Pusan National University, Busandaehakro 63 Bungil 2, Geumjeong-Gu, Busan, 46241, Republic of Korea. Hauptthemen laut MEDLINE: Atrial Fibrillation, Percutaneous Coronary Intervention, Stroke. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Triple antithrombotic therapy (TAT), a combination of an oral anticoagulant and dual antiplatelet therapy (DAPT), is a key treatment for prevention of ischemic events in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI). However, TAT is not extensively used because of the risk of bleeding. This study aimed to determine the utilization and influencing factors of TAT using real-world data in the non-vitamin K antagonist oral anticoagulants (NOACs) era. METHODS: We analyzed National Inpatient Sample data compiled by the Health Insurance Review & Assessment Service (HIRA-NIS) from 2011 to 2020. Patients with AF who underwent PCI with stent implantation and with an increased stroke risk were selected as candidates for TAT therapy. Demographic and clinical factors associated with TAT use were investigated using the chi-squared test and the Student t-test, and influencing factors were identified using multiple logistic regression. RESULTS: The TAT utilization rate steadily increased from 30.3% in 2011 to 65.4% in 2020 (Cochran-Armitage trend test: p < 0.001) with an average of 45.9%. Positive influencing factors for TAT use were identified as congestive heart failure, history of previous stroke/transient ischemic attack/thromboembolism, valvular heart disease, and year. Negative influencing factors included insurance type (medical aid or Patriots & Veterans Insurance), type of medical institution (general hospitals or primary medical institutions), and comorbidities such as renal disease, liver disease, and history of the previous hemorrhage. CONCLUSIONS: The utilization of TAT following PCI among high-stroke risk AF patients steadily increased from 2011 to 2020, reaching 65.4% by the end of the study period. However, in 2020, a significant proportion of 29.4% of patients still received DAPT, indicating that many AF patients undergoing PCI did not receive adequate antithrombotic therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Pusan National University, Busandaehakro 63 Bungil 2, Geumjeong-Gu, Busan, 46241, Republic of Korea.
- College of Pharmacy, Woosuk University, Samnye-ro 443 Samnye-eup, Wanju-gun, Jeollabuk-do, 55338, Republic of Korea. sspark@woosuk.ac.kr.
- College of Pharmacy, Pusan National University, Busandaehakro 63 Bungil 2, Geumjeong-Gu, Busan, 46241, Republic of Korea. jenk@pusan.ac.kr.
Zitieren
APA
Choi, H. J., Lee, Y., Park, S., & Je, N. K. (2023). Utilization of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. European Journal of Clinical Pharmacology, 79(4), 541-551. https://doi.org/10.1007/s00228-023-03468-6
Vancouver
Choi HJ, Lee Y, Park S, Je NK. Utilization of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. European Journal of Clinical Pharmacology. 2023;79(4):541-551. doi:10.1007/s00228-023-03468-6
BibTeX
@article{Choi2023,
author = {Choi, Hye-Jeong and Lee, Yonghyuk and Park, Susin and Je, Nam Kyung},
title = {Utilization of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention},
journal = {European Journal of Clinical Pharmacology},
year = {2023},
volume = {79},
number = {4},
pages = {541--551},
doi = {10.1007/s00228-023-03468-6}
}
EUVIMED